Rab6a-Based Prenylation Assay for REP1 Activity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for determining the activity of Rab escort protein 1 (REP1) in the context of choroideremia treatment are not sensitive enough, particularly when using Rab27a as a prenylation substrate, which results in weak signals and low sensitivity, making them unsuitable for reliable screening of gene therapy vectors.
Innovation Solution
Using Rab6a as a substrate in a prenylation reaction with REP1 and Rab geranylgeranyltransferase, along with a lipid donor substrate, to detect the lipidated Rab6a product, which provides a more sensitive and reliable method for assessing REP1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Rab27a is used as a prenymlation substrate in the assay, then the assay can be performed with existing protocols, but the signal strength is weak and sensitivity is low
Solution Approach 1:
The patent changes the substrate parameter from Rab27a to Rab6a, which fundamentally alters the assay characteristics. Rab6a produces stronger prenymlation signals and higher sensitivity while maintaining assay reliability, directly resolving the contradiction between reliability and sensitivity.
2Ease of manufacture
If Rab27a is used as a substrate, then the assay protocol is established, but the signal-to-noise ratio is low making it unsuitable for screening
Solution Approach 1:
By changing the substrate from Rab27a to Rab6a, the patent achieves a significantly improved signal-to-noise ratio that enables reliable screening of gene therapy vectors, while the assay remains straightforward to perform.
3Adaptability or versatility
If existing assay methods are used for REP1 activity determination, then the methodology is available, but the sensitivity is insufficient for quality control screening
Solution Approach 1:
The patent modifies the existing assay by substituting Rab6a for Rab27a as the substrate, transforming it into a high-sensitivity tool suitable for quality control screening of gene therapy vectors while maintaining the overall assay framework.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the sensitivity and signal-to-noise ratio of the assay, allowing for accurate and reliable determination of REP1 activity, particularly for AAV gene therapy vectors, and is suitable for quality control analysis of gene therapy vectors.
Implementation Method 1
detecting the lipidated Rab6a product
Data Source
Figure 1A~1
Figure 2A~2
Figure 3A~3
AI summary
A method for determining the activity of Rab escort protein 1 (REP1) comprising the steps: (a) providing a sample comprising REP1; (b) contacting the sample of step (a) with Rab6a, Rab geranylgeranyltransferase (Rab GGTase) and a lipid donor substrate; and (c) detecting the lipidated Rab6a product.